Axxcess Wealth Management LLC Acquires 43,296 Shares of Pfizer Inc. $PFE

Axxcess Wealth Management LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 27.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 203,514 shares of the biopharmaceutical company’s stock after purchasing an additional 43,296 shares during the period. Axxcess Wealth Management LLC’s holdings in Pfizer were worth $5,186,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC boosted its position in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after buying an additional 1,820,634 shares during the period. Norges Bank bought a new position in Pfizer in the 2nd quarter worth about $2,270,157,000. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC raised its stake in shares of Pfizer by 2.0% during the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after acquiring an additional 950,239 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.41 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a market capitalization of $155.82 billion, a PE ratio of 20.15 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a 50-day simple moving average of $25.91 and a two-hundred day simple moving average of $25.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the business posted $0.63 EPS. Pfizer’s revenue was down 1.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Finally, Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.